Arcturus Therapeutics (ARCT)

Arcturus focuses on infectious disease vaccines as well as rare diseases affecting the liver and respiratory system. Its vaccine work includes COVID-19 and influenza candidates, with KOSTAIVE among its most prominent programs. KOSTAIVE is a self-amplifying mRNA COVID-19 vaccine developed with partners and represents a key example of the company’s approach to next-generation RNA immunization. Other vaccine candidates include LUNAR-FLU and updated COVID-19 formulations such as KOSTAIVE XBB.1.5.

Beyond vaccines, Arcturus is advancing therapeutic candidates that use RNA to address genetic disease biology. LUNAR-OTC targets ornithine transcarbamylase deficiency, a rare liver disorder, while LUNAR-CF is being developed for cystic fibrosis, a respiratory disease caused by CFTR dysfunction. These programs reflect the company’s broader strategy of using RNA to instruct cells to produce functional proteins or therapeutic antigens.

Arcturus operates as a single business focused on the discovery, development, manufacturing support, and potential commercialization of RNA medicines. For investors, ARCT represents exposure to the RNA therapeutics field, where scientific progress, clinical trial results, regulatory decisions, manufacturing scale-up, and commercial partnerships can all materially influence the company’s prospects.